Jose Manuel, MD
Family Medicine · Sarasota, FLNPI 1558625863
Payments from drug & device makers
Across 187 payments — averaging $18.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$470
- GSK$444
- Bayer$403
- Pfizer$352
- Novartis$325
- Exact Sciences$303
- plus $1K from 16 others
What the payments were for
- Food & beverage$3,487100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 28 | $470 |
| GSK | 28 | $444 |
| Bayer | 16 | $403 |
| Pfizer | 22 | $352 |
| Novartis | 18 | $325 |
| Exact Sciences | 11 | $303 |
| Novo Nordisk | 13 | $239 |
| Amgen | 12 | $206 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 9 | $180 |
| AstraZeneca | 10 | $166 |
| AbbVie | 5 | $119 |
| Daiichi Sankyo Inc. | 3 | $64 |
| Boehringer Ingelheim | 2 | $43 |
| Philips North America LLC | 2 | $37 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $22 |
| Bausch Health US, LLC | 1 | $21 |
| Vertos Medical, Inc. | 1 | $21 |
| Amarin Pharma, Inc. | 1 | $18 |
| Nevro Corp. | 1 | $16 |
| Biohaven Pharmaceuticals, Inc. | 1 | $15 |
| Corcept Therapeutics | 1 | $14 |
| Merck | 1 | $13 |
How this compares
$3,487 in reported general payments places this provider in the 80th percentile of 7,282 family medicine providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 110 | $124,999 |
| JardianceEmpagliflozin | 110 | $108,313 |
| OzempicSemaglutide | 86 | $99,426 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 60 | $58,486 |
| MounjaroTirzepatide | 36 | $37,382 |
| LinzessLinaclotide | 38 | $25,776 |
| EntrestoSacubitril/Valsartan | 19 | $21,180 |
| XareltoRivaroxaban | 19 | $20,421 |
| Tresiba Flextouch U-100Insulin Degludec | 24 | $19,290 |
| FarxigaDapagliflozin Propanediol | 18 | $16,382 |
| Tresiba Flextouch U-200Insulin Degludec | 20 | $15,205 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 22 | $14,840 |
| TrulicityDulaglutide | 13 | $13,168 |
| Repatha SureclickEvolocumab | 13 | $9,228 |
| VascepaIcosapent Ethyl | 22 | $9,190 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $352 | $124,999110 claims |
| Boehringer IngelheimJardiance | $43 | $108,313110 claims |
| Novo NordiskOzempic | $239 | $99,42686 claims |
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta | $444 | $81,279100 claims |
| Lilly USA, LLCMounjaro, Trulicity | $470 | $50,55049 claims |
| AbbVieLinzess | $119 | $25,77638 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $166 | $24,45331 claims |
| NovartisEntresto | $325 | $21,18019 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 7,282 family medicine providers in Florida.
Other family medicine in Sarasota
- Niaz AusafSarasota$3.8M
- Hugh ColemanDaytona Beach$115.5M
- Alexander WhiteDaytona Beach$69.7M
- Ronald SurowitzJupiter$38.3M
- Bruce RankinDeland$36.7M
- Keila HooverMiami$33.7M
- John NardandreaOcala$30.8M
- Jorge CasoMiami$22.6M
- Sharrell CooperPalm Coast$16.9M
- Christopher GallowayMelbourne$15.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.